Managing leprosy reactions with secukinumab: Insights from a case series.

Background

Erythema nodosum leprosum (ENL) is an immunological inflammatory reaction requiring precise management. Recalcitrant cases, their refractoriness to conventional therapy, and the adverse effects of standard treatments underline the need to explore alternative therapeutic options.

Methods

We conducted a retrospective study of five patients treated with secukinumab between January 2023 and January 2025.

Results

Patients showed clinical improvement with a reduced ENL frequency, neuritis relief, and corticosteroid sparing.

Conclusions

Secukinumab appears to be a promising corticosteroid-sparing option for ENL, with a favorable safety profile. Further studies are required to confirm the efficacy and long-term safety of this treatment regimen.